DOI: https://doi.org/10.53350/pjmhs22169579

**ORIGINAL ARTICLE**

# Early Autosomal-Dominant Polycystic Kidney Disease is Related to Liver and Cyst Volumes, Hepatic Parenchyma Volume, and Patient-Reported Effects

FAIZAN BANARAS[1], NAVEED FAZAL[2], MUHAMMAD FARHAN NASIR[3], MUHAMMAD ZAFAR RANA[4], AHMAD MUMTAZ BANDAY[5], ADEEL BASHIR[6]

*[1]PGR Medicine & Allied, Ayub Teaching Hospital Abbottabad, KPK*
*[2]Medical Officer, Iqbal Hospital Fateh Jang Attock*
*[3]Assistant Professor, Department of Zoology, Division of Science and Technology, University of Education Lahore Vehari Campus*
*[4]Ayub Medical College*
*[5]PG Radiology, SKBZ CMH Muzzaffarabad*
*[6]Ayub Teaching Hospital Abbottabad*
*Correspondence to: Faizan Banaras, Email: faizanbanaras958@gmail.com*

## ABSTRACT

**Aim:** Polycystic liver infections are the most prevalent extra renal manifestation of autosomal-dominant polycystic kidney disease (PKD). People are living longer and there are more chances of spread on infections and these infections may cause different diseases but these can be improved by providing the proper knowledge among the lay men and control over these diseases can be made like better kidney survival, less death from heart disease, new treatments for kidney transplants, and more people with polycystic liver failure. There is a lack of research that completely characterizes PKD in big cohorts. Many other researchers has also been made to observe the size of the liver and the number of cysts which are linked to the size of the hepatic parenchyma, but this study is the specific to the polycystic kidney disease and its effect over the liver with the volume of cyst**.** This is the only studyin the region. .

**Methods:** cross-sectional studies has been conducted to investigate the relationship between the initial volumes of the liver which was determined by MRI, and the patient's demographics, the outcomes of these results also depends upon the quality of life of the patients. This research was conducted from January 2021 to June 2021 at Mayo Hospital, Lahore Pakistan. The information is gathered from the randomized, placebo-controlled trial that is currently being conducted at five tertiary-care medical facilities. In this the comparison was made between the groups of angiotensin I–converting enzyme inhibitor and an angiotensin II–receptor blocker. These findings were based on the normal situation o fthe blood [ressure. Because normal blood pressure related with the proper renal functioning. These tests were performed for 558 patients with ADPK (age, 16–50 y). Practical implication: We can easily implement these findings to PKD in hospitals and find the best treatment method according to this.

**Results:** The significant level of hepatomegaly was seen in number of individuals diagnosed with ADPKD. Hepatomegaly was also existed in cysts as well as parenchyma. Cysts were found more often in women, and both the liver and cyst sizes were observed to be larger in women with the increase in age. Patients whose illness had progressed significantly demonstrated a significant reduction in the situation of liver parenchyma. In this study some minor irregularities were noticed in the results of laboratory testing on the liver, and splenomegaly and hypersplenism remained related to the severity of PLD. Inferior quality of life was connected with having a larger amount of damage in the liver tissue.

**Conclusion:** Even in the earliest stages of ADPKD, hepatomegaly is rather prevalent, and it cannot be diagnosed properly just by the presence of cysts. Even for those who didn't have cysts, parenchymal volumes have been discovered to be substantially bigger than liver volumes in people without ADPKD or these predicted by basic tests performed in the specific laboratories. The harshness of PLD remained linked to changed biochemical also hematologic characteristics, in addition to a worse quality of life in patients.

**Keywords:** Hepatomegaly, Polycystic liver infections, extra-renal manifestation, autosomal-dominant polycystic kidney diseases.

## INTRODUCTION

The most frequent kind of monogenic kidney disease in addition to fourth biggest reason for kidney failure throughout the world is autosomal dominant polycystic kidney illness[1]. The most prevalent extra-renal appearance of this condition is polycystic liver disease, which may be randomly determined as the occurrence of any liver cyst[2]. Some people have chronic symptoms due to swelling in the liver, this liver swelling may lead to damage for the life. However, most people with liver cysts do not have any symptoms, such situations are called as silent cystic situations. Signs of PLD are issues experienced by the number of hepatic cysts or by the cysts taken by the individual, including bleeding, rupture, or infection. Massive enlargement of the liver may also cause the damage of the digestive system, blood vessels, and the diaphragm that are located nearby[3]. As a consequence of the decline in cardiovascular activity, as well as the extension of renal survival and life expectancy for those receiving renal replacement treatments, the prevalence of PLD with severe symptoms has increased. Interventions such as cyst aspiration including the sclerosis, fenestration and with the combination of liver excision and cyst fenestration, hepatic artery embolization, and, in the most severe situations, liver or consolidated liver-kidney transplantation may be compulsory for survival of some patients. Here have recently been a number of specified interventional medical tests has been reported with the aim of putting off the advancement and creating new ways of diagnosis of PLD for as long as possible[4]. There is not a single study that has completely defined the PLD load in large ADPKD populations. The complete clinical significance of this phenomenon is not fully recognized, That is the reason that this categorization is necessary. The HALT Advancement of Polycystic Kidney Failure Research is increasing da by day and the most comprehensive cohort of ADPKD patient populations through liver and kidney imaging is studied in this research[5].

The objectives of this study was to get a full picture of how PLD affects the man and how it causes the death in our cohort and to know about the link between the diagnosis of PLD identified by MRI and other relevant regular medical laboratory tests and their statistics.

## METHODOLOGY

The HALT-PKD-A experimental remains a multi-center, randomized, and non - randomized research that is investigating the consequence of blockade of a renin-angiotensin-aldosterone framework on overall kidney volume as well renal functions in

different peoples through ADPKD; suitability requirements, also the styling of the protocol have been posted already. Our current research was conducted from January 2021 to June 2021 at Mayo Hospital, Lahore Pakistan. The additional techniques provide a comprehensive explanation of the approaches that were used. The volume of kindly and liver was measured by adopting a technique known as segmentation technique. The specific area of the organs was used for the measurements by adopting the specific techniques and by ocnsioder4ong these values the over all weight and length of the kidney and liver was calculated. The mean differences were also used to measure the accurate values. Chi acquired test was applied on the values for the statistical analysis and these analysis were made for measuring the significant and non-significant situations of the samples.

## RESULTS

It was found in the present study that total liver volume (LV) was greater in females than of males (270 males; 293 females) (Figure 1A and B; accessible for 563 people) than it was in females (191/859 mL) (P .0002 for comparisons between male and females). The differences in the values on behalf of gender was not measured to a significant level.once height was taken into account: males had a value of 1118 407 mL/m, while females had a value of 1145 524 mL/m (Table 1, Figure 1A). Individuals with ADPKD were found to have LVs that were considerably bigger in both sexes compared to those that were observed in a sample of prospective liver donors and for the regular populations as a whole. The use of the consistent solution for Caucasians resulted in LVs that remained greater than these expected for similar individuals suffering from HALT-PKD and ADPKD (Table 2). Height-dependent liver parenchymal volume was shown to be greater in males, whereas height-adjusted total liver capacity remained measured to be greater in women (Table 1). Researchers especially in variance the liver parenchymal volume in the cohort to anticipate in addition detected normal LVs in the regular populations. We did this to determine if cyst advancement completely accounts for hepatomegaly. Researchers found that the LPV in our cohort seems to be much higher than LVs in liver transplant living donors (P =.0002), the LVs revealed in normal participants (P =.0002), and LVs projected for our individuals to use the standard equation. Even among these people who did not have any liver cysts, this was a key indication (P .0002).

As was to be predicted, the htLCV had a positive correlation through length over-all liver volume, especially in acute PLD (Figure 1A; women: r = 0.68; men: r = 0.49). As soon as the htLCV reaches a certain threshold, which is around 710 mL/m, the htLPV no longer continues to rise (Figures 1B, 2A, and 2B). The majority of the individuals from females, hence inclinations of htLV, htLCV, and htLPV (shown in Figure 1B) were responsible for lesser LPVs in females when individuals who did not have liver cysts (1558 287 mL vs 1738 449 mL; P =.0002) (Table 2). Therefore, despite the fact that LPV was either normal or bigger in comparison to normal, relative decreases in htLPV happened in population of selected patient having acute PLD who made up the bulk of ADPKD individuals (Figure 1B).

In this study the categories according to the severity of PLD into mild, moderate, in addition unadorned levels by using statistics presented in Figure 1B. Researcher's changes periodically that someone had mild PLD if their htLV was less than 1100 mL/m, and we decided that someone had moderate PLD if their htLV would have been between 1100 and 1900 mL/m. We characterized acute PLD as having an htLV that was larger than 1900 mL/m (women, 82 percent), which was consonant with the plateauing of htLPV at our current cut-off point and corresponded to htLCV that was larger than about 710 mL/m. The features of patients, including their demographics, laboratory results, and imaging findings, are compared and contrasted in Table 2. Alternately, one may utilize arbitrary htLCV cut-off standards to determine the presence of illness. Patients who had severe PLD remained grownup (females in their 40s), had the lesser platelet count, albumin level, eGFR, and standard of living, also had advanced alkaline phosphatase levels, alanine aminotransferase levels, in addition height-adjusted spleen volumes. Patients who had severe PLD also had a high prevalence of splenomegaly, which is an increase in the volume of the spleen relative to (Figure 2C).

In the extreme PLD group, serum albumin and blood platelet levels reported to the found at the lower level, although serum ALP levels, spleen volume, in addition to physical role were found to be greater (Table 1). The ALT level was shown to have a correlation with htLV and htLPV in both males and females (Table 1, Table 2). The levels of ALP and aspartate aminotransferase associated favorably with htLV (P =.0043 and P =.0472, correspondingly), but levels of serum albumin negatively associated with htLV (P =.0043) and htLPV (P .0002) for this study (Supplementary Table 2). After taking into account the participants' ages, the significance of the correlations among ALP, ALT, or serum albumin level also constant in females that was not affected (P =.002, P =.002, and P =.004, correspondingly). Even after taking into account the effect of age, there was still a link among ALT and either htLV or htLPV in males (P less than.007).




Image 1:




Image 2:

Table 1:

| Variable | htLV (2) 1000–1800 mL/m (moderate PLD) (n ¼ 268) | htLV (3) >1800 mL/m (severe PLD) (n ¼ 29) | htLV (1) <1000 mL/m (mild PLD) (n ¼ 240) | P-value |
|---|---|---|---|---|
| Standardized physical component, n | 52.1 _ 7.4 (259) | 49.8 _ 8.4 | 52.5 _ 7.3 (224) | .1906 |
| Role emotional, n | 90.4 _ 19.8 (258) | 84.5 _ 20.5 | 90.2 _ 18.4 (223) | .3041 |
| Mental health, n | 77.3 _ 14.5 (259) | 74.5 _ 12.4 | 77.8 _ 15.8 (225) | .5415 |
| Standardized mental component, n | 50.7 _ 8.6 (259) | 48.4 _ 9.4 | 51.0 _ 9.6 (224) | .3544 |

Table 2:

| Characteristics | Female (N ¼ 280; 49%) | | Male (N ¼ 289; 51%) | | P-value |
|---|---|---|---|---|---|
| | Mean _ SD | n | Mean _ SD | n | |
| Dynamic figures | | | | | |
| Weight, kg | 272 | 74.3 _ 16.4 | 276 | 90.5 _ 15.5 | <.0002a |
| Age, y | 275 | 37.6 _ 8.4 | 283 | 35.7 _ 8.1 | .007a |
| BMI, kg/m2 | 273 | 26.8 _ 5.7 | 274 | 27.7 _ 4.5 | .045a |
| Height, cm | 271 | 166.5 _ 6.5 | 275 | 181.0 _ 7.8 | <.0002a |
| DBP home | 180 | 83.0 _ 7.4 | 192 | 82.2 _ 8.1 | .2955 |
| BSA, m2 | 271 | 1.8 _ 0.2 | 274 | 2.1 _ 0.2 | <.0002a |
| SBP home | 180 | 121.3 _ 8.9 | 192 | 126.6 _ 9.3 | <.0002a |
| Image analysis | | | | | |
| htLV, mL/m | 264 | 1141.2 _ 517.6 | 258 | 1115.2 _ 405.5 | .7250b |
| Patients with liver cysts, % | 210 | 78.7 | 185 | 69.3 | .0138a |
| LV, mL | 268 | 1904.6 _ 859.5 | 266 | 2021.8 _ 748.5 | .0002a,b |
| LPV | 276 | 1593.8 _ 336.7 | 269 | 1900.2 _ 343.9 | <.0002a,b |
| LCV, mL | 272 | 310.8 _ 763 | 268 | 121.6 _ 647.6 | <.0002a,b |
| htLCV, mL/m | 263 | 184.3 _ 459.3 | 259 | 64.6 _ 351.3 | <.0002a,b |

## DISCUSSION

Limited research has been conducted to study the influence of PLD considering the relevance it plays in ADPKD. In the large group of individuals having ADPKD also chronic renal disease phases 1 and 2, the HALT-PKD-A study offers the possibility of correlating MR imaging with medical, biochemical, and other characteristics[6]. The existence of PLD or its severity was not one of the criteria used to classify individuals in this study. So, even though this cohort is a carefully picked selection of individuals to ADPKD, prejudices favoring the inclusion or exclusion of individuals with serious PLD that did not effect recruitment. This is because the recruitment process was unbiased. This research provides a number of unexpected data that expand our knowledge of PLD[7].These results go beyond just validating the widely held belief that the frequency and harshness of PLD is greater in females when associated to males. Detected LVs (in both men and women) remained substantially greater than in overall population, and in females, LPVs remained much bigger than LVs anticipated for similar individuals. Additionally, LVs projected for the general public were considerably lower than actual LVs[8]. The observation of higher LPV in comparison with normal shows that hepatomegaly may not remain totally compensated for through macroscopic cysts detected via MRI. This is because the LPV was found to be elevated. There is also the possibility that hepatocyte, hyperplasia or hypertrophy is a factor in the development of hepatomegaly[9]. In reality, this new evaluation is equivalent to the latest identification of hepatocyte hypertrophy in the mouse model of ADPKD and PLD caused either through placement of human PKD1 mutation, in addition to demonstration of strength that polycystic 1 and polycystic 2 remain carried in hepatocytes, wherein its condensed appearance or function can be a main reason of the hepatocyte hypertrophy. It is interesting to note that many cytokines and growth factors that are thought to be involved in hepatic regeneration following a loss in liver mass are up-regulated in PLD[10].

Regardless of the context of hepatomegaly, the liver parenchyma and function were found to be normal in research that was conducted in the past on a smaller scale. According to the findings of our investigation, people suffering from severe PLD had a somewhat lower LPV. As a result, a hepatomegaly diagnosis in PLD is linked to just slight changes in liver laboratory tests and only slight reductions in thrombocytopenia. Splenic cysts only have been recorded anecdotally, despite the fact that the link between splenic cysts and pancreatic cysts is widely known.

## CONCLUSION

For the purpose of providing a clearer concept of PLD existence in the humans, researchers have utilized information from the HALT-PKDA cohort. Previous research has shown that MRI is a good method for measuring kidney volume in ADPKD. Currently, kidney volume is being explored by way of the biomarker of cancer intensity. Researchers illustrate a link among MRI-measured LVs through initial biochemical disturbances also QOL, demonstrating its validity for conformation quality indicators for drug testing in PLD by demonstrating this association. During the course of this research project, successive continuous imaging will be used to determine liver growth rates and get a greater comprehension of the clinical spectrum of PLD and its associated consequences.

## REFRENCES


1. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2019;67:792–810.
2. Willey CJ, et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2019;32:1356–63.
3. Spithoven EM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2018;29(Suppl 4):15–25.
4. Cheong B, Muthupillai R, Rubin MF, Flamm SD. Normal values for renal length and volume as measured by magnetic resonance imaging. Clin J Am Soc Nephrol. 2017;2:38–45.
5. Reeders ST, et al. A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. Nature. 2021;317:542–4
6. Peters DJ, et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet. 2016;5:359–62.
7. Hopp K, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 2019;122:4257–73.
8. Leeuwen ISL, et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet. 2014;13:3069–77.
9. Porath B, et al. Mutations in GANAB, encoding the glucosidase iiα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet. 2018;98:1193–207.
10. Cornec-Le Gall E, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet. 2018;102:832–44.